LakeShore Biopharma Directors Depart
Ticker: LSBWF · Form: 6-K · Filed: Jun 10, 2024 · CIK: 1946399
| Field | Detail |
|---|---|
| Company | Lakeshore Biopharma CO., LTD. (LSBWF) |
| Form Type | 6-K |
| Filed Date | Jun 10, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 5 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-departure, corporate-governance, filing-update
TL;DR
LakeShore Biopharma directors OUT, including Shetty & Mehta. Big changes brewing?
AI Summary
LakeShore Biopharma Co., Ltd. (formerly YS Biopharma Co., Ltd. and YishengBio Co., Ltd.) filed a Form 6-K on June 10, 2024. The filing indicates the departure of several directors, including Dr. Ajit Shetty, Dr. Viren Mehta, Mr. Haitao Zhao, Mr. Henry Chen, and Mr. Pierson Yue Pan. The company is incorporated in E9 and its fiscal year ends on March 31.
Why It Matters
The departure of multiple directors can signal internal changes or strategic shifts within the company, potentially impacting its future direction and investor confidence.
Risk Assessment
Risk Level: medium — Director departures can indicate internal instability or strategic disagreements, which poses a moderate risk to the company's operations and future performance.
Key Players & Entities
- LakeShore Biopharma Co., Ltd. (company) — Registrant
- Dr. Ajit Shetty (person) — Departing Director
- Dr. Viren Mehta (person) — Departing Director
- Mr. Haitao Zhao (person) — Departing Director
- Mr. Henry Chen (person) — Departing Director
- Mr. Pierson Yue Pan (person) — Departing Director
- YS Biopharma Co., Ltd. (company) — Former Company Name
- YishengBio Co., Ltd (company) — Former Company Name
FAQ
When did LakeShore Biopharma Co., Ltd. change its name from YS Biopharma Co., Ltd.?
The date of name change from YS Biopharma Co., Ltd. was March 10, 2023.
Who are the directors that have departed from LakeShore Biopharma?
The directors who have departed are Dr. Ajit Shetty, Dr. Viren Mehta, Mr. Haitao Zhao, Mr. Henry Chen, and Mr. Pierson Yue Pan.
What is the filing date of this Form 6-K?
This Form 6-K was filed on June 10, 2024.
What is the primary business address of LakeShore Biopharma?
The primary business address is Building No. 2, 38 Yongda Road, Daxing Biomedical Industry Park, Daxing District, Beijing, PRC.
Does LakeShore Biopharma file annual reports under Form 20-F or Form 40-F?
LakeShore Biopharma indicates it files annual reports under Form 20-F.
Filing Stats: 1,356 words · 5 min read · ~5 pages · Grade level 11 · Accepted 2024-06-10 07:01:02
Filing Documents
- ea0207563-6k_lakeshore.htm (6-K) — 20KB
- 0001213900-24-050958.txt ( ) — 21KB
Legal Proceedings
Legal Proceedings Since December 2023, the Company has been involved in several legal proceedings in the Cayman Islands against Mr. Yi Zhang, the former chairperson of the Board, and his associates. On December 22, 2023, the Grand Court of the Cayman Islands (the “Court”) granted the Company an injunction order against Mr. Zhang, which restrained Mr. Zhang from, among other things, taking any steps to exercise any powers of, or hold himself out to be, chairperson of the Board. That injunction was discharged by the Court on February 6, 2024. On February 16, 2024, the Company obtained another injunction order from the Court which restrained Mr. Zhang and his associates, including Nan Zhang, Yun (Monica) Zhang, Lui Chi Keung and Jing Xian Li from, among other things, holding themselves out to be directors of the Company and from taking any steps to exercise any powers as though they were directors. On April 3, 2024, the Company filed an amended statement of claim with the Court in its proceedings against Mr. Zhang and his associates. The amended statement of claim seeks various forms of declaratory and injunctive relief against the defendants as well as damages. On June 7, 2024, Mr. Zhang filed a defense with the Court which, among other things, alleges that certain present and former directors of the Company took steps to improperly oust Mr. Zhang from, and to seize control of, the Company and that certain present and former directors of the Company breached their fiduciary duties to the Company (which Mr. Zhang has pleaded will be the subject of separate derivative proceedings) and denies the Company’s entitlement to the relief the Company has claimed in its amended statement of claim. On February 20, 2024, Mr. Zhang filed a writ of summons (the “Writ of Summons”) with the Court against the Company and certain of its directors and executive officers and Apex Prospect Limited (“Apex”), seeking, amongst other things, (i) a d